Identification and Characterization of LRRC37BP1, A Potential Drug Target and Biomarker

Target Name: LRRC37BP1

NCBI ID: G147172

LRRC37BP1

Other Name(s): Leucine rich repeat containing 37B pseudogene 1 | LRRC37B2 | leucine rich repeat containing 37B pseudogene 1

Identification and Characterization of LRRC37BP1, A Potential Drug Target and Biomarker

The Leucine Rich Repeat (LRRC) domain is a highly conserved family of non-coding RNA molecules that have been identified in a variety of organisms, including humans. LRRCs have been shown to play important roles in various cellular processes, including gene regulation, DNA replication, and cell signaling. One of the LRRCs, LRRC37BP1, has been identified as a potential drug target or biomarker and is of interest to researchers due to its unique structure and function.

Structure and Function

LRRC37BP1 is a 29 base pair RNA molecule that contains a unique LRRC repeat unit. The LRRC repeat is a short sequence of four amino acids that is repeated in the RNA molecule multiple times. The LRRC repeat unit is composed of the amino acids Lys-Arg -Glu-Asp and is repeated three times in the RNA molecule. This repeating unit is flanked by a single base pair of AUG and a single base pair ofCG.

LRRC37BP1 is a non-coding RNA molecule, which means that it does not encode any functional RNA molecule. However, it is known to play a role in regulating gene expression. Studies have shown that LRRC37BP1 can interact with several protein molecules, including the protein encoded by the gene USP4. This interaction between LRRC37BP1 and USP4 has been shown to alter the stability of USP4 and influence its function in various cellular processes.

LRRC37BP1 has also been shown to play a role in the regulation of DNA replication. Studies have shown that LRRC37BP1 can interact with the protein encoded by the gene MLL. This interaction between LRRC37BP1 and MLL has been shown to alter the structure and function of MLL and influence its role in DNA replication.

LRRC37BP1 has also been shown to play a role in cell signaling. Studies have shown that LRRC37BP1 can interact with the protein encoded by the gene CSR. This interaction between LRRC37BP1 and CSR has been shown to alter the structure and function of CSR and influence its role in cell signaling.

Drug Targeting

LRRC37BP1 has been identified as a potential drug target due to its unique structure and function. Studies have shown that LRRC37BP1 can interact with several protein molecules, including the protein encoded by the gene USP4. This interaction between LRRC37BP1 and USP4 has been shown to alter the stability of USP4 and influence its function in various cellular processes.

In addition, LRRC37BP1 has also been shown to play a role in the regulation of DNA replication. Studies have shown that LRRC37BP1 can interact with the protein encoded by the gene MLL. This interaction between LRRC37BP1 and MLL has been shown to alter the structure and function of MLL and influence its role in DNA replication.

Furthermore, LRRC37BP1 has also been shown to play a role in cell signaling. Studies have shown that LRRC37BP1 can interact with the protein encoded by the gene CSR. This interaction between LRRC37BP1 and CSR has been shown to alter the structure and function of CSR and influence its role in cell signaling.

Conclusion

LRRC37BP1 is a unique non-coding RNA molecule that has been identified in various organisms, including humans. Its structure and function have been shown to play important roles in various cellular processes, including gene regulation, DNA replication, and cell signaling. As a result , LRRC37BP1 has

Protein Name: Leucine Rich Repeat Containing 37B Pseudogene 1

The "LRRC37BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC37BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets